drugset / Trial / NCT03292406
A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
RandomizedParallel-groupDouble-blindTreatment
Summary
To assess the efficacy, safety and pharmacokinetics in participants treated with CD11301 gel vs. placebo for early stage CTCL (IA, IB, or IIA).
Timeline
- Start
- 2017-12-19
- Primary completion
- 2020-03-17
- Completion
- 2020-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resiquimod | Small molecule | 0.03 % | Topical |
| Subject | Resiquimod | Small molecule | 0.06 % | Topical |